Paragon’s Portfolio Company – Emalex Biosciences – Raises $250 Million in Series D Financing to Fund Tourette’s Clinical Trial

Emalex Biosciences, a portfolio company of Paragon Biosciences, recently secured a Series D funding of $250 million for its upcoming Phase 3 Tourette syndrome trial.